MESALAMINE (mesalamine) by Gen Pharmaceuticals is understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Approved for mildly to moderately active ulcerative colitis, for the maintenance of remission of ulcerative colitis, ulcerative colitis. First approved in 2026.
Drug data last refreshed 20h ago
understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids,…
Worked on MESALAMINE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)